Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition - 24/02/23
Doi : 10.1016/j.jaad.2022.09.012
Ted V. Jacoby, BS a, b, Nishi Shah, BS a, c, Maria S. Asdourian, MPhil a, d, Leah L. Thompson, MD a, d, e, Tracey S. Otto, MD a, f, Nicole R. LeBoeuf, MD d, g, h, Yevgeniy Semenov, MD a, d, Edward Christopher Dee, MD i, Kerry L. Reynolds, MD d, j, Steven T. Chen, MPH, MS-HP-Ed a, d, ⁎ 
a Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
b University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu, Hawaii
c Virginia Common Wealth University School of Medicine, Richmond, Virginia
d Harvard Medical School, Boston, Massachusetts
e Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
f Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
g Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
h Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts
i Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
j Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts
∗Correspondence to: Steven T. Chen, MPH, MS-HP-Ed, Department of Dermatology, Massachusetts General Hospital, 50 Staniford St Ste 200, Boston, MA 02114Department of DermatologyMassachusetts General Hospital50 Staniford St Ste 200BostonMA02114
Key words : cutaneous immune-related adverse event, dermatology consultation, immune checkpoint inhibitor, immunotherapy, skin toxicity
| Jacoby and Shah contributed equally to this work. |
|
| Funding sources: STC is supported by a Medical Dermatology Career Development Award from the Dermatology Foundation. ECD is funded in part through the NIH/NCI Support Grant P30 CA008748. NRL is supported by NIH/NCI grant U54-CA225088. |
|
| IRB approval status: Approved by Mass General Brigham IRB (Protocol No. 2017P000501). |
|
| Statement of patient consent: All patients gave consent for their medical information to be published in print and online for the public to view. |
|
| Reprints not available from the authors. |
© 2022
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 88 - N° 3
P. 711-714 - mars 2023 Retour au numéro
Article précédent
- Demographic characteristics, factors influencing specialty choice, and intended career goals of graduating medical students pursuing careers in rural dermatology
- Travis S. Fulk, Katelyn J. Rypka, Laurel L. Wessman, Ronda S. Farah, Kevin J. Gaddis, Robert T. Brodell, Cindy Firkins Smith, Matthew D. Mansh
- Random skin biopsies for diagnosis of intravascular large B-cell lymphoma: Retrospective analysis of 31 biopsies from a US dermatology inpatient consultative service with literature review
- Sa Rang Kim, Christine J. Ko, Caroline A. Nelson, Sarika Ramachandran, Jeff R. Gehlhausen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?